MedTrace Logo

Consumer Health Study Aims to Evaluate the Safety, Tolerability and Impact of ED02 Probiotic Supplement on Gastrointestinal Outcomes

NCT07423897 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-04-01

No results posted yet for this study

Summary

The Study Team identified Bifidobacterium pseudocatenulatum ED02 as a safe and effective probiotic strain isolated from a healthy human donor. Research by the Study Team indicates that this strain lacks harmful genetic traits and can successfully mitigate infections from hypervirulent pathogens like Klebsiella pneumoniae without adverse effects.

Conditions

  • Gastrointestinal
  • Gut Health

Interventions

DIETARY_SUPPLEMENT

Bifidobacterium pseudocatenulatum

Probiotic Supplement

DIETARY_SUPPLEMENT

Placebo

Matching placebo

Sponsors & Collaborators

  • People Science, Inc.

    collaborator INDUSTRY

  • Synbiotic Health

    lead INDUSTRY

Principal Investigators

  • Noah Craft, M.D., Ph.D. · People Science, Inc.

  • Azure Grant · People Science, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2026-06-17
Completion
2026-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07423897 on ClinicalTrials.gov